Simon Baldacci
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Simon Baldacci has a total of 201 co-authors. Here are the top co-authors by number of shared publications:
- Marie-Anaïs Locquet
Dana-Farber Cancer Institute, Boston, Massachusetts
177 shared publications - Pasi A. Janne
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA
177 shared publications - William W. Feng
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA
161 shared publications - Alessandro Di Federico
University of Bologna 1 Department of Medical and Surgical Sciences Bologna, Italy
147 shared publications - Biagio Ricciuti
Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
147 shared publications - Danielle Haradon
Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA
147 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Overview of MET TKD mutations detected in pan-cancer cohorts. (A) Type (missense, truncating, splice site, in-frame) of MET TKD mutations detected in the cohort #1 (711 MET TKD mutations among 664 unique patients with a tumor harboring MET TKD mutations without concurrent METex14 alterations). (B) Type of MET TKD mutations according to OncoKB annotation (biological function: oncogenic / likely oncogenic, unknown) detected in cohort #1. (C) Distribution of MET TKD mutations across MET kinase domain for cohort #1. (D) Type (missense, truncating, splice site, in-frame) of MET TKD mutations detected in cohort #2 (2,559 MET TKD mutations among 2,477 unique patients with a tumor harboring MET TKD mutations without concurrent METex14 alterations). (E) Type of MET TKD mutations according to OncoKB annotation (biological function: oncogenic / likely oncogenic, unknown) detected in cohort #2. (F) Distribution of MET TKD mutation across MET kinase domain for cohort #2.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Overview of MET TKD mutations detected in pan-cancer cohorts. (A) Type (missense, truncating, splice site, in-frame) of MET TKD mutations detected in the cohort #1 (711 MET TKD mutations among 664 unique patients with a tumor harboring MET TKD mutations without concurrent METex14 alterations). (B) Type of MET TKD mutations according to OncoKB annotation (biological function: oncogenic / likely oncogenic, unknown) detected in cohort #1. (C) Distribution of MET TKD mutations across MET kinase domain for cohort #1. (D) Type (missense, truncating, splice site, in-frame) of MET TKD mutations detected in cohort #2 (2,559 MET TKD mutations among 2,477 unique patients with a tumor harboring MET TKD mutations without concurrent METex14 alterations). (E) Type of MET TKD mutations according to OncoKB annotation (biological function: oncogenic / likely oncogenic, unknown) detected in cohort #2. (F) Distribution of MET TKD mutation across MET kinase domain for cohort #2.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Frequency of MET tyrosine kinase domain (TKD) mutations in cohort #2 according to amino acid residue, out of a total of 2,559 MET TKD mutations.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Frequency of MET tyrosine kinase domain (TKD) mutations in cohort #2 according to amino acid residue, out of a total of 2,559 MET TKD mutations.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 12 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Sensitivity pattern of MET TKD mutations in 293T cells. (A) ERK-mediated transcriptional activation assessed by luciferase assay in 293T cells co-transfected with MET WT or TKD mutant constructs, an ERK activation reporter vector (pGL4.33), and a control co-reporter vector (pRL-TK). The lower panel shows western blot analysis of transfected samples. (B) Western blot analysis of MET and ERK1/2 phosphorylation in response to 1 μM crizotinib. MET TKD mutants showing sensitivity and resistance to crizotinib are colored in green and orange, respectively.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 12 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Sensitivity pattern of MET TKD mutations in 293T cells. (A) ERK-mediated transcriptional activation assessed by luciferase assay in 293T cells co-transfected with MET WT or TKD mutant constructs, an ERK activation reporter vector (pGL4.33), and a control co-reporter vector (pRL-TK). The lower panel shows western blot analysis of transfected samples. (B) Western blot analysis of MET and ERK1/2 phosphorylation in response to 1 μM crizotinib. MET TKD mutants showing sensitivity and resistance to crizotinib are colored in green and orange, respectively.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 13 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Concurrent driver mutations according to oncogenic / likely oncogenic MET TKD mutations detected in cohort #2.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 13 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Concurrent driver mutations according to oncogenic / likely oncogenic MET TKD mutations detected in cohort #2.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 14 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Western blot analysis of MET and ERK1/2 phosphorylation in MET R1170Q cell models. MET and ERK1/2 phosphorylation in (A) Ba/F3 cells stably transduced with MET R1170Q and (B) 293T cells transiently overexpressing MET R1170Q. Cells were treated with MET TKIs at the indicated dose for Ba/F3 cells or at 1 μM for 293T cells.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 14 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Western blot analysis of MET and ERK1/2 phosphorylation in MET R1170Q cell models. MET and ERK1/2 phosphorylation in (A) Ba/F3 cells stably transduced with MET R1170Q and (B) 293T cells transiently overexpressing MET R1170Q. Cells were treated with MET TKIs at the indicated dose for Ba/F3 cells or at 1 μM for 293T cells.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 25 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
TCGA PanCancer Atlas Studies included in cohort #1 downloaded from cBioPortal.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 25 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
TCGA PanCancer Atlas Studies included in cohort #1 downloaded from cBioPortal.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 12 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Characteristics of 129 NSCLC cases harboring oncogenic / likely oncogenic MET TKD mutations from cohort #2.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 12 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Characteristics of 129 NSCLC cases harboring oncogenic / likely oncogenic MET TKD mutations from cohort #2.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
List of missense mutations with unknown biologic function and their pathogenicity scores using all three in silico tools in cohorts #2
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
List of missense mutations with unknown biologic function and their pathogenicity scores using all three in silico tools in cohorts #2
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 11 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Detailed genomic characteristics for each case of NSCLC with oncogenic / likely oncogenic MET tyrosine kinase domain (TKD) mutations in cohort #1.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 11 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Detailed genomic characteristics for each case of NSCLC with oncogenic / likely oncogenic MET tyrosine kinase domain (TKD) mutations in cohort #1.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 10 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Characteristics of 44 NSCLC cases harboring oncogenic / likely oncogenic MET TKD mutations in cohort #1.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 10 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Characteristics of 44 NSCLC cases harboring oncogenic / likely oncogenic MET TKD mutations in cohort #1.